N/A
N=49
Smoking Cessation Intervention for Women Living With HIV
AIDS/HIV
Bottom Line
View on ClinicalTrials.gov: NCT02898597 ↗Enrolled (actual)
49
Serious AEs
2.0%
Results posted
Aug 2019
Primary outcome: Primary: Number of Participants With Abstinence — 8; 1 Participants — p=< 0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Cognitive Behavioral Therapy (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of Massachusetts, Boston
- Primary completion
- Dec 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Abstinence |
8; 1 | < 0.05 sig |
Summary
As people with HIV/AIDS live longer, the burden of non-AIDS-related health problems such as cardiovascular diseases and cancers on these people have consistently increased. Smoking is one of the major contributing factors to these health problems and rates of cigarette smoking in this group are substantially higher than those of the general population: 40-70% vs. 17-10%. Especially, women living with HIV/AIDS seem to be more susceptible to the negative consequence of smoking than their male counterparts. They are also less likely to see tobacco dependence treatment for dual stigma associated with both conditions: HIV infection and nicotine addiction. This is a pilot study to develop smoking cessation intervention for these women.
Eligibility Criteria
Inclusion Criteria
- English speaking
- Diagnosis of HIV infection
- Age 18 or older
- Smoking at least 5 cigarettes a day
- Having access to a mobile-phone with Internet connection
- Willing to quit smoking within the next 4 weeks
Exclusion Criteria
- Inability to speak English
- Involvement in another cessation program
- Being pregnant or lactating
- Having an active skin disease
- History of serious mental illnesses (e.g., schizophrenia and bipolar disorder)
- Serious alcohol use problem
- Use of any illegal substances excluding marijuana
Data sourced from ClinicalTrials.gov (NCT02898597). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.